Prior COVID-19 Diagnosis, Severe Outcomes, and Long COVID among U.S. Adults, 2022
Vaccines · 17.06.2024 · 12 (6) · 669
DOI: 10.3390/vaccines12060669 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 17.06.2024. Verfasst von Kimberly H Nguyen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Tufts University, National Cancer Institute (NCI).
Abstract (Originalsprache)
Given the increase in COVID-19 emergency department visits and hospitalizations during the winter of 2023–2024, identifying groups that have a high prevalence of COVID-19 cases, severity, and long-term symptoms can help increase efforts toward reducing disparities and prevent severe COVID-19 outcomes. Using data from the 2022 National Health Interview Survey (n = 27,651), we assessed the prevalence of COVID-19 outcomes (prior diagnosis, moderate/severe COVID-19, and long COVID) by sociodemographic characteristics and factors associated with each COVID-19 outcome. Approximately one third of adults reported a prior COVID-19 diagnosis (30.7%), while one half (51.6%) who had COVID-19 reported moderate or severe symptoms, and one fifth (19.7%) who had COVID-19 symptoms reported long COVID. The following were associated with higher odds of moderate/severe COVID-19 and long COVID: havinga high-risk condition (aOR = 1.20, OR = 1.52); having anxiety or depression (OR = 1.46, OR = 1.49); having a disability (OR = 1.41, OR = 1.60); and having a food insecurity (OR = 1.37, OR = 1.50) compared to a lack of these conditions. Having two or more COVID-19 vaccinations was associated with lower odds of a COVID-19 diagnosis (OR = 0.75), moderate/severe COVID-19 (OR = 0.86), and long COVID (OR = 0.82). Improving vaccination coverage and reducing disparities in COVID-19 outcomes could advance health equities and protect against future resurgence of disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
- Department of Public Health & Community Medicine, Tufts University School of Medicine, Boston, MA 02111, USA.
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
- Emory Vaccine Center, Emory University, Atlanta, GA 30317, USA.
- Department of Civil and Environmental Engineering, Tufts University School of Engineering, Medford, MA 02155, USA.
ORCID-Profile: Kimberly H Nguyen, Siyu Chen, Laura Corlin
Förderung
- NCI NIH HHS
- Tufts University
- National Cancer Institute (NCI)
Zitieren
APA
Nguyen, K. H., Bao, Y., Chen, S., Bednarczyk, R. A., Vasudevan, L., & Corlin, L. (2024). Prior COVID-19 Diagnosis, Severe Outcomes, and Long COVID among U.S. Adults, 2022. Vaccines, 12(6), 669. https://doi.org/10.3390/vaccines12060669
Vancouver
Nguyen KH, Bao Y, Chen S, Bednarczyk RA, Vasudevan L, Corlin L. Prior COVID-19 Diagnosis, Severe Outcomes, and Long COVID among U.S. Adults, 2022. Vaccines. 2024;12(6):669. doi:10.3390/vaccines12060669
BibTeX
@article{Nguyen2024,
author = {Nguyen, Kimberly H and Bao, Yingjun and Chen, Siyu and Bednarczyk, Robert A and Vasudevan, Lavanya and Corlin, Laura},
title = {Prior COVID-19 Diagnosis, Severe Outcomes, and Long COVID among U.S. Adults, 2022},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {6},
pages = {669},
doi = {10.3390/vaccines12060669}
}
EUVIMED